Charles Moore
Stock Analyst at Robert W. Baird
(0.21)
# 4,768
Out of 5,189 analysts
11
Total ratings
n/a
Success rate
-38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Moore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Reiterated: Buy | $126 → $107 | $20.40 | +424.51% | 4 | Nov 3, 2026 | |
| CTNM Contineum Therapeutics | Downgraded: Hold | $19 → $14 | $8.68 | +61.29% | 4 | Oct 14, 2026 | |
| DNLI Denali Therapeutics | Reiterated: Buy | $34 | $18.45 | +84.28% | 3 | Aug 7, 2026 |
Bright Minds Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $126 → $107
Current: $20.40
Upside: +424.51%
Contineum Therapeutics
Oct 14, 2026
Downgraded: Hold
Price Target: $19 → $14
Current: $8.68
Upside: +61.29%
Denali Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $34
Current: $18.45
Upside: +84.28%